Wirkung von Thrombininhibitoren auf ein humanes, experimentelles Thrombosemodell zur Vermeidung von Tierversuchen

Zusammenfassung

Die Entwicklungen neuer Antithrombotika mit Wirkung auf das Gerinnungssystem oder die Rezeptoren der Thrombozyten stellen einen wichtigen Schwerpunkt in der medizinischen Forschung dar. Im Rahmen dieser Entwicklungsprojekte sind die Ergebnisse zur Wirksamkeit in Thrombosemodellen am Tier von entscheidender Bedeutung. Ihre Übertragbarkeit auf den Menschen wird jedoch kritisch beurteilt. In einem Ex-vivo-Thrombosemodell mit humanem Vollblut wurden daher zunächst die Dosisabhängigkeit von Thrombininhibitoren geprüft, um die Aussagefähigkeit des Modells zu belegen.

Summary

The development of new antithrombotic drugs on the blood coagulation system and on receptors of platelets represents an important area of medical research. The results of the efficacy in animal models are of critical importance for the further development to man. The transferability of such data from animal to human species still remains critical. The antithrombotic effects of direct thrombin inhibitors were investigated in an ex vivo thrombosis model with human blood in order to analyse the feasibility of such model.

Schlüsselwörter

Thrombosemodell - Antithrombotika - Thrombininhibitoren - Blutgerinnung - Thrombozyten

Keywords

Thrombosis model - antithrombotic drugs - thrombin inhibitors - blood coagulation - platelets

• Literatur

• 1 Hara T, Yokoyama A, Morishima Y, Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 1995; 80: 99-104.
• 2 Tapparelli C, Metternich R, Gfeller P, Gafner B, Powling M. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin. Thromb Haemost 1995; 73: 641-7.
• 3 Dickneite G, Seiffge D, Diehl KH, Reers M, Czech J, Weinmann E, Hoffmann D, Stuber W. Pharmacological characterization of a new 4-amidinophenylalanine thrombin-inhibitor (CRC 220). Thromb Res 1995; 77: 357-68.
• 4 Shirakura S, Higo K, Takeda M, Karasawa A. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol 1994; 65: 93-8.
• 5 Aguejouf O, Imbault P, Jourdan A, Doutremepuich F, Juaneda M, Doutremepuich C. Experimental models of arterial thrombosis. Ann Cardiol Angiol Paris 1995; 44: 109-18.
• 6 Gray E, Tubbs J, Thomas S, Oates A, Biosclair M, Kemball-Cook G, Barrowcliffe TW. Measurement of activated factor IX in factor IX concentrates: Correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-9.
• 7 Orvim U, Barstad RM, Vlasuk GP, Sakariassen KS. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 2188-94.
• 8 Hirigoyen MB, Zhang WX, Weinberg H. A standardized model of microvenous thrombosis. J Reconstr Microsurg 1995; 11: 455-9.
• 9 Delon-Martin C, Vogt C, Chignier E, Guers C, Chapelon JY, Cathignol D. Venous thrombosis generation by means of high-intensity focused ultrasound. Ultrasound Med Biol 1995; 21: 113-9.
• 10 Krupinski K, Ferber H, Breddin HK, Bielawiec M. The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests. Acta Haematol POl 1994; 25: 235-42.
• 11 Jourdan A, Aguejouf O, Imbault P, Doutremepuich F, Inamo J. Experimental thrombosis model induced by free radicals. Application to aspirin and other different substances. Thromb Res 1995; 79: 109-23.
• 12 Saniabadi AR, Umemura K, Matsumoto N, Sakuma S, Nakashima M. Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemost 1995; 73: 868-72.
• 13 Harenberg I. Thrombin-antithrombin (TAT) complexes. In: Jespersen J, Bertina RM, Haverkate F. (eds). ECAT Assay Procedures. Laboratory techniques in thrombosis. A manual. 2nd revised edition. Dordrecht, Boston, London: Kluwer Academic Publishers; 1998: 209-16.
• 14 Harenberg J, Schuler M, Waibel St, Heptner W, Zimmermann R. Influence of low molecular weight heparin on fibrin formation and platelet aggregation. Haemost 1985; 15: 29-30.